Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Omega Protein Announces Fourth Quarter and Full Year 2013 Financial Results

      Omega Protein Corporation Logo. (PRNewsFoto/Omega Protein Corporation) (PRNewsFoto/)

      News provided by

      Omega Protein Corporation

      Mar 10, 2014, 07:00 ET

      Share this article

      Share this article


      HOUSTON, March 10, 2014 /PRNewswire/ -- Omega Protein Corporation (NYSE:OME), a nutritional product company and a leading integrated producer of omega-3 fish oil and specialty protein products, today reported financial results for the fourth quarter and full year ended December 31, 2013.

      Fourth Quarter and Full Year 2013 Highlights

      • Revenues:  $66.0 million for the quarter and $244.3 million for the year
      • Gross profit margin:  42.4% for the quarter and 33.9% for the year
      • Net income:  $9.7 million, or $14.2 million excluding plant closure charges and net gain on disposal of assets, for the quarter, and $30.5 million, or $35.0 million excluding plant closure charges and net loss on disposal of assets, for the year
      • Earnings:  Earnings per diluted share of $0.45, or $0.66 excluding plant closure charges and net gain on disposal, for the quarter, and $1.45, or $1.66 excluding plant closure charges and net loss on disposal,  for the year
      • Adjusted EBITDA:  $26.7 million for the quarter and $75.6 million for the year

      "We are pleased with the progress made on our strategic objectives in 2013, as we continued to build a more balanced nutrition company focused on value-added products that allow families to live healthier lives through nutrition.  Our strong financial performance during the year included increased revenues, as well as record gross profit and gross margin," commented Bret Scholtes, Omega Protein's President and Chief Executive Officer.  "In the quarter, our financial results benefited from record human nutrition revenue, attractive animal nutrition forward contract pricing, and a productive end to the 2013 fishing season."

      Mr. Scholtes concluded, "We are excited to build on this progress in 2014 as we introduce additional capacity and capabilities to capitalize on our market opportunities."

      Fourth Quarter 2013 Results

      The Company's revenues increased 4% from $63.1 million in the same period last year to $66.0 million.  This increase was due to a $4.4 million increase in human nutrition revenue, partially offset by a $1.6 million decrease in animal nutrition revenues.  The increase in human nutrition revenues was primarily due to sales of protein products from Wisconsin Specialty Protein ("WSP"), a business acquired by the Company in the first quarter of 2013.  The decrease in animal nutrition revenues was primarily due to a 33% decrease in the Company's fish meal sales volumes, partially offset by a 109% increase in fish oil sales volumes and increased sales prices of 19% and 15% for the Company's fish meal and fish oil, respectively.  The composition of revenue by nutritional product line for the fourth quarter of 2013 was 59% fish meal, 26% fish oil, 14% specialty nutraceutical and food ingredients and products, and 1% fish solubles and other. 

      Fourth quarter of 2013 revenues decreased 25% from $87.6 million in the third quarter of 2013 to $66.0 million.  This decrease was due to a $23.2 million decrease in animal nutrition revenues, which reflected decreased sales volumes of 19% and 53% for fish meal and fish oil, respectively, and a 5% decrease in fish meal sales prices, partially offset by a 30% increase in fish oil sales prices.  The increase in fish oil sales prices was primarily due to a change in the product mix of higher priced refined and lower priced crude oils, and higher prices on those crude oil volumes.  Human nutrition revenues increased $1.6 million to $9.4 million in the fourth quarter compared to $7.8 million in the third quarter.  The increase in human nutrition revenues primarily reflects higher sales of OmegaActiv fish oil and other nutraceutical ingredients. 

      The Company reported gross profit of $28.0 million, or 42.4% as a percentage of revenues, for the fourth quarter of 2013, versus $12.9 million, or 20.5% as a percentage of revenues, in the fourth quarter of 2012.  The increase was due to an increase in the animal nutrition segment gross profit as a percentage of revenues from 20.1% to 47.1% as a result of increased fish oil and fish meal sales prices and greater than anticipated fish catch in the fourth quarter.  As a result of this greater fish catch and production, standard cost for 2013 inventory, for which sales commenced largely in the third quarter of 2013, was decreased and all previous sales of 2013 inventory production were adjusted during the fourth quarter ended December 31, 2013. This increase in gross profit as a percentage of revenues was partially offset by a decrease in the human nutrition segment gross profit as a percentage of revenues from 24.9% to 13.6%, due primarily to lower gross profit as a percentage of revenues for other nutraceuticals and the addition of the protein products business.

      Compared to the third quarter of 2013, fourth quarter gross profit decreased from $29.4 million to $28.0 million; however, gross profit as a percentage of revenues increased from 33.6% to 42.4%.  The increase in gross profit as a percentage of revenues was due to an increase in animal nutrition gross profit as a percentage of revenues from 34.5% to 47.1% primarily as a result of the lower inventory cost associated with greater than anticipated fish catch after September 30, 2013, as discussed above.  The human nutrition segment gross profit as a percentage of revenues decreased from 24.6% to 13.6% primarily due to lower gross profit as a percentage of revenues for protein products and changes in product mix. 

      Selling, general and administrative expenses for the fourth quarter increased $0.5 million to $5.9 million compared to the fourth quarter of 2012, primarily as a result of the WSP acquisition.  Selling, general and administrative expenses decreased from $6.9 million for the third quarter of 2013, primarily as a result of decreased employee compensation related costs.

      In the fourth quarter of 2013, the Company closed its menhaden fish processing plant located in Cameron, Louisiana and re-deployed certain vessels from that facility to the Company's other Gulf Coast facilities located in Abbeville, Louisiana and Moss Point, Mississippi, as previously announced.  In conjunction with the closure, the Company incurred charges of $6.6 million in the fourth quarter of 2013.  

      The fourth quarter of 2013 effective tax rate was 31.9% compared to 126.2% in the fourth quarter of 2012 and 34.6% in the third quarter of 2013. The higher effective tax rate in the fourth quarter of 2012 was primarily the result of charges relating to a U.S. Attorney investigation that were non-deductible for tax purposes. 

      Net income for the fourth quarter of 2013 was $9.7 million ($0.45 per diluted share) compared to a net loss of $0.5 million ($0.03 loss per diluted share) for the same period last year and net income of $14.0 million ($0.66 per diluted share) for the third quarter of 2013.  Excluding plant closure charges and net gain on disposal of assets, net income for the fourth quarter of 2013 would have been $14.2 million ($0.66 per diluted share) and excluding the impact of the charges related to the U.S. Attorney investigation and net loss on disposal of certain assets, net income for the fourth quarter of 2012 would have been $4.0 million ($0.20 per diluted share).

      Adjusted EBITDA totaled $26.7 million for the fourth quarter of 2013, compared to $11.6 million for the same period last year and $27.1 million for the third quarter of 2013.

      Full Year 2013 Results

      Revenues for the year ended December 31, 2013 increased 4% to $244.3 million compared to revenues of $235.6 million for the year ended December 31, 2012. The increase in revenues for 2013 was due to a $9.1 million increase in human nutrition revenues partially offset by a $0.4 million decrease in animal nutrition revenues. The increase in human nutrition revenues was due primarily to the acquisition of WSP in the first quarter of 2013. The decrease in animal nutrition revenues was primarily due to decreased sales volumes of 28% for the Company's fish meal, partially offset by increased sales prices of 23% for the Company's fish meal and increased sales volumes and prices of 2% and 43%, respectively, for the Company's fish oil.

      The Company reported record gross profit of $82.8 million, or 33.9% as a percentage of revenues, for the year ended December 31, 2013, versus gross profit of $42.1 million, or 17.8% as a percentage of revenues, for the year ended December 31, 2012. The increase in gross profit as a percentage of revenues was primarily due to an increase in animal nutrition segment gross profit as a percentage of revenues from 17.3% to 36.2%, reflecting an increase in animal segment revenues per unit as a result of higher fish meal and fish oil sales prices, partially offset by a decrease in human nutrition gross profit as a percentage of revenues from 22.8% to 18.2%.

      Net income for the year ended December 31, 2013 was $30.5 million ($1.45 per diluted share) compared to $4.1 million ($0.20 per diluted share) for the same period last year.  Excluding plant closure charges and net loss on disposal of assets, net income for 2013 would have been $35.0 million ($1.66 per diluted share) and excluding the impact of U.S. Attorney investigation charges and net gain on disposal of assets, net income for the year ended December 31, 2012 would have been $10.4 million ($0.52 per diluted share). 

      Adjusted EBITDA totaled $75.6 million for the year ended December 31, 2013, an increase from $35.6 million for the previous year.

      Balance Sheet

      The Company's balance sheet remains strong, and stockholders' equity increased $41.6 million to $247.2 million as of December 31, 2013 as compared to $205.6 million at December 31, 2012.  Total debt decreased $3.1 million from December 31, 2012 to $24.2 million on December 31, 2013.  The Company's December 31, 2013 cash balance decreased $21.9 million from December 31, 2012 to $34.1 million. This decrease was primarily due to the acquisition of WSP in the first quarter of 2013, as well as expenditures related to 2013 fishing season, capital spending and debt payments, and was partially offset by the sale of inventory.

      Conference Call Information

      Omega Protein will host a conference call on its fourth quarter and full year 2013 financial results at 8:30 a.m., Eastern Time, on Monday, March 10, 2014. The Company's senior management team will be available to discuss recent financial results and current business trends as well as respond to questions.

      Please dial (877) 407-3982 domestically or (201) 493-6780 internationally to join the call. Interested parties may also listen to the webcast live over the Internet at www.omegaprotein.com.

      A webcast replay of the conference call will be available beginning shortly after the conclusion of the call at www.omegaprotein.com and will be available for 30 days. A telephonic replay of the conference call will be available through March 24, 2014. Domestic listeners can dial (877) 870-5176, and international listeners may dial (858) 384-5517. The replay access code 13576105.

      About Omega Protein

      Omega Protein Corporation (NYSE:OME) is a century old nutritional company that develops, produces and delivers healthy products throughout the world to improve the nutritional integrity of functional foods, dietary supplements and animal feeds.  Omega Protein's mission is to help people lead healthier lives with better nutrition through sustainably sourced ingredients such as highly-refined omega-3 rich fish oil, specialty proteins and nutraceuticals.

      Forward Looking Statements

      SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS: The statements contained in this press release that are not historical facts are forward-looking statements that involve a number of risks and uncertainties. Forward-looking information may be based on projections, predictions and estimates. Some statements in this press release may be forward-looking and use words like "may," "may not," "believes," "do not believe," "expects," "do not expect," "anticipates," "do not anticipate," "see," "do not see," "should," or other similar expressions. The actual results of future events described in any of these forward-looking statements could differ materially from those stated in the forward-looking statements. Important factors that could cause actual results to be materially different from those forward-looking statements include, among others: (1) the Company's ability to meet its raw material requirements through its annual menhaden harvest, which is subject to fluctuations due to natural conditions over which the Company has no control, such as varying fish population, fish oil yields, adverse weather conditions, natural and other disasters and disease; (2) the impact of laws and regulations that may be enacted that may restrict the Company's operations or the sale of the Company's products; (3) the impact of worldwide supply and demand relationships on prices for the Company's products; (4) the Company's expectations regarding demand and pricing for its products proving to be incorrect, and the effect of forward sales of products on the Company's financial results; (5) fluctuations in the Company's quarterly operating results due to the seasonality of the Company's business, estimates of standard cost for inventory and subsequent adjustments to such costs, and the Company's deferral of inventory sales based on worldwide prices for competing products; (6)the Company's ability to realize the anticipated benefits from its acquisitions in the human nutrition business, Nutegrity; (7) the Company's expectations regarding Nutegrity, its future prospects and the dietary supplement market or the human health and wellness segment generally, proving to be incorrect; (8) the cost of compliance with existing and future government regulations; (9) the impact of the Company's settlement with U.S. Attorney's Office on the Company's operations and financial results, including the impact of any failure to comply with the terms of the Company's probation or the limitations imposed on the Company's ability to secure government contracts or loans under the NFMS Title XI program; (10) the impact of the closure of the Company's Cameron, Louisiana processing plant on the Company's operations and financial results; and (11) the cost of compliance or potential restrictions on sales caused by laws and regulations regarding fish meal or oil importation into foreign jurisdictions.  Other factors are described in further detail in the Company's filings with the Securities and Exchange Commission, including its reports on Form 10-K, Form 10-Q and Form 8-K.

      OMEGA PROTEIN CORPORATION


      CONSOLIDATED BALANCE SHEETS




      December 31,

      2013


      December 31,

      2012



      (in thousands)

      ASSETS







       Current assets:







                Cash and cash equivalents


      $

      34,059


      $

      55,998

                Receivables, net



      21,140



      17,267

                Inventories



      94,339



      66,659

                Deferred tax asset, net



      1,062



      1,165

                Prepaid expenses and other current assets



      3,915



      3,430








                      Total current assets



      154,515



      144,519

      Other assets, net



      5,234



      10,789

      Property, plant and equipment, net



      144,113



      127,640

      Goodwill



      19,600



      7,986

      Other intangible assets, net



      7,932



      4,362








                      Total assets


      $

      331,394


      $

      295,296








      LIABILITIES AND STOCKHOLDERS' EQUITY














      Current liabilities:







               Current maturities of long-term debt


      $

      3,112


      $

      3,058

               Current portion of capital lease obligation



      —



      268

               Accounts payable



      5,380



      3,000

               Accrued liabilities



      29,145



      31,741

                    Total current liabilities



      37,637



      38,067

      Long-term debt, net of current maturities



      21,130



      24,242

      Deferred tax liability, net



      19,351



      15,794

      Pension liabilities, net



      4,117



      9,826

      Other long-term liabilities



      1,929



      1,764








                      Total liabilities



      84,164



      89,693















      Commitments and contingencies                                                 














      Stockholders' equity:







              Preferred stock, $0.01 par value; 10,000,000 authorized shares; none

      issued



      —



      —

              Common Stock, $0.01 par value; 80,000,000 authorized shares;

      20,804,189 and 19,883,940 shares issued and outstanding at December 31, 2013 and 2012, respectively



      203



      195

              Capital in excess of par value



      136,428



      129,040

              Retained earnings



      116,807



      86,292

              Accumulated other comprehensive loss



      (6,208)



      (9,924)

                      Total stockholders' equity



      247,230



      205,603

                          Total liabilities and stockholders' equity


      $

      331,394


      $

      295,296








      OMEGA PROTEIN CORPORATION


      CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

      (in thousands, except per share amounts)



      Three Months Ended December 31,


      Years Ended December 31,


      2013


      2012


      2013


      2012

      Revenues

      $        65,973


      $        63,133


      $      244,293


      $      235,639

      Cost of  sales

      38,023


      50,214


      161,543


      193,583









      Gross profit

      27,950


      12,919


      82,750


      42,056









      Selling, general and administrative expenses

      5,890


      5,364


      25,293


      21,737

      Research and development expenses

      637


      537


      2,407


      2,209

      Loss related to plant closure

      6,597


          ―


      6,597


                    ―

      Charges related to U.S. Attorney investigation

              ―


      3,550


                   ―


      7,990

      Impairment of intangible assets

      186


            ―


      266


      129

      (Gains) loss on disposal of assets

      (39)


      1,117


      174


      (2,635)

      Operating  income

      14,679


      2,351


      48,013


      12,626









      Interest income

      3


      11


      18


      32

      Interest expense

      (302)


      (339)


      (1,658)


      (1,335)

      Other expense, net

      (109)


      (83)


      (394)


      (365)









      Income before income taxes

      14,271


      1,940


      45,979


      10,958

      Provision for income taxes

      4,553


      2,448


      15,464


      6,895

      Net income (loss)

      $        9,718


      $          (508)


      $       30,515


      $         4,063









      Other comprehensive (loss) income:
















      Energy swap adjustment, net of tax expense (benefit) of $83,($142), $81 and $241 respectively

      156


      (263)


      151


      448

      Pension benefits adjustment, net of tax expense (benefit) of  $1,515, ($233), $1,920 and $165, respectively

      2,812


      (433)


      3,565


      307

      Comprehensive income (loss)

      $      12,686


      $      (1,204)


      $       34,231


      $        4,818

      Basic earnings (loss) per share

      $          0.47


      $        (0.03)


      $           1.50


      $          0.21









      Weighted average common shares outstanding

      20,248


      19,463


      19,913


      19,420









      Diluted earnings (loss) per share

      $          0.45


      $        (0.03)


      $           1.45


      $          0.20









      Weighted average common shares and potential common shares outstanding

      20,942


      19,857


      20,634


      19,874









      OMEGA PROTEIN CORPORATION

      CONSOLIDATED STATEMENTS OF CASH FLOWS

      (in thousands)

       



      Years Ended December 31,  



      2013


      2012

      Cash flows from operating activities:





             Net income

      $

      30,515

      $

      4,063

             Adjustments to reconcile net income (loss) to net

               cash  provided by operating activities:





              Depreciation and amortization


      21,056


      17,999

              Loss disposal of assets, plant closure


      5,514


                                                              ―

              (Gain) loss on disposal of assets, net


      174


      (2,635)

              Impairment of intangible assets


      266


      129

              Provisions for losses on receivables


      103


      48

              Share based compensation


      1,982


      3,721

              Deferred income taxes


      3,579


      2,272

              Changes in assets and liabilities:





                       Receivables


      (2,630)


      (494)

                         Inventories


      (26,855)


      (1,766)

                       Prepaid expenses and other current assets


      (191)


      (616)

                       Other assets


      4,092


      (6,379)

                       Accounts payable


      1,644


      (779)

                       Accrued liabilities


      (5,250)


      11,855

                       Pension liability, net


      (2,144)


      (735)

                       Other long-term liabilities


      165


      52






                               Net cash provided by operating activities


      32,020


      26,735

      Cash flows from investing activities:





              Proceeds from disposition of assets


      470


      6,152

              Acquisition of InCon, net of cash acquired


                                                              ―


      181

              Acquisition of Wisconsin Specialty Protein, net of

               cash acquired


      (26,676)


                                                              ―

              Acquisition of Cyvex, net of cash acquired


                                                              ―


                                                              ―

              Land and building purchased in capital lease

               extinguishment


      (5,005)


                                      ―

              Capital expenditures


      (24,796)


      (25,064)






                               Net cash used in

                                 investing activities


      (56,007)


      (18,731)






      Cash flows from financing activities:





              Principal payments of long-term debt


      (3,058)


      (2,994)

              Principal payments of capital lease obligation


      (309)


      (517)

              Debt issuance costs


                                                              ―


      (389)

              Proceeds from stock options exercised


      4,009


      469

              Tax effect of stock options exercised


      1,406


      34






                              Net cash provided by (used in) financing   

                                  activities


      2,048


      (3,397)






      Net  (decrease) increase in cash and cash equivalents


      (21,939)


      4,607

      Cash and cash equivalents at beginning of year


      55,998


      51,391

      Cash and cash equivalents at end of year

      $

      34,059

      $

      55,998






      The tables below present information about reported segments for the quarters ended December 31, 2013 and 2012 (in thousands):

      Quarter Ended December 31, 2013


      Animal Nutrition


      Human Nutrition


      Unallocated


      Total

      Revenue


      $   56,618


      $   9,355


        $          ―


      $   65,973

      Cost of sales


      29,945


      8,078


                   ―


      38,023

      Gross profit


      26,673


      1,277


                   ―


      27,950

      Selling, general and administrative expenses (including research and development)


      721


      1,878


      3,928


      6,527

      Loss related to plant closure


      6,597


                 ―


                   ―


      6,597

      Other (gains) and losses


      (74)


      226


      (5)


      147

      Operating income (loss)


      $   19,429


      $    (827)


      $  (3,923)


      $   14,679

      Depreciation and amortization


      $     4,594


      $      648


      $       187


      $     5,429

      Quarter Ended December 31, 2012


      Animal Nutrition


      Human Nutrition


      Unallocated


      Total

      Revenue


      $   58,173


      $    4,960


      $          ―


      $   63,133

      Cost of sales


      46,490


      3,724


                    ―


      50,214

      Gross profit


      11,683


      1,236


                    ―


      12,919

      Selling, general and administrative expenses (including research and development)


      731


      969


      4,201


      5,901

      Charges related to U.S. Attorney investigation


      3,550


                  ―


                    ―


      3,550

      Other (gains) and losses


      1,117


                  ―


                    ―


      1,117

      Operating income (loss)


      $     6,285


      $       267


      $  (4,201)


      $     2,351

      Depreciation and amortization


      $     3,956


      $       348


      $       387


      $     4,691

      The tables below present information about reported segments for the years 2013 and 2012 (in thousands):

      2013


      Animal Nutrition


      Human Nutrition


      Unallocated


      Total

      Revenue


      $ 213,236


      $   31,057


        $           ―


      $  244,293

      Cost of sales


      136,146


      25,397


                 ―


      161,543

      Gross profit


      77,090


      5,660


                 ―


      82,750

      Selling, general and administrative expenses (including research and development)


      2,744


      6,959


      17,997


      27,700

      Loss related to plant closure


      6,597


                  ―


                  ―


      6,597

      Other (gains) and losses


      140


      305


      (5)


      440

      Operating income (loss)


      $   67,609


      $   (1,604)


      $ (17,992)


      $   48,013

      Depreciation and amortization


      $   17,946


      $     2,369


      $        741


      $   21,056

      2012


      Animal Nutrition


      Human Nutrition


      Unallocated


      Total

      Revenue


      $ 213,624


      $   22,015


        $           ―


      $ 235,639

      Cost of sales


      176,588


      16,995


                  ―


      193,583

      Gross profit


      37,036


      5,020


                  ―


      42,056

      Selling, general and administrative expenses (including research and development)


      2,564


      3,795


      17,587


      23,946

      Charges related to U.S. Attorney investigation


      7,990


                  ―


                  ―


      7,990

      Other (gains) and losses


      (2,635)


      129


                  ―


      (2,506)

      Operating income (loss)


      $   29,117


      $     1,096


      $ (17,587)


      $   12,626

      Depreciation and amortization


      $   15,859


      $     1,315


      $        825


      $   17,999

      Adjusted EBITDA to Net Income Reconciliation
      The following tables (in thousands) provide a reconciliation of Adjusted EBITDA, a non-GAAP (Generally Accepted Accounting Principles) financial measure, to net income, the most directly comparable financial measure calculated and presented in accordance with GAAP, for the three months ended December 31, 2013, September 30, 2013 and December 31, 2012 and the full year ended December 30, 2013 and 2012:



      Three Months Ended



      December 31, 2013


      September 30, 2013


      December 31, 2012

      Net Income (Loss)

      $

      9,718

      $

      13,962

      $

      (508)

      Reconciling items:







           Interest expense


      272


      452


      309

           Income tax provision


      4,553


      7,377


      2,448

           Depreciation and amortization


      5,429


      5,374


      4,691

           Loss related to plant closure


      6,597


      —


      —

           Charge related to U.S. Attorney investigation


      —


      —


      3,550

           Impairment of intangible assets


      186


      80


      —

           Net (gain) loss on disposal of assets


      (39)


      (161)


      1,117

      Adjusted EBITDA

      $

      26,716

      $

      27,084

      $

      11,607








      Year Ended





      December 31, 2013


      December 31, 2012



      Net Income

      $

      30,515

      $

      4,063



      Reconciling items:







           Interest expense


      1,536


      1,201



           Income tax provision


      15,464


      6,895



           Depreciation and amortization


      21,056


      17,999



           Loss related to plant closure


      6,597


      —



           Charge related to U.S. Attorney investigation


      —


      7,990



           Impairment of intangible assets


      266


      129



           Net (gain) loss on disposal of assets


      174


      (2,635)



      Adjusted EBITDA

      $

      75,608

      $

      35,642



      Adjusted EBITDA represents net income before interest expense, income tax, depreciation and amortization, charges related to U.S. Attorney investigation, impairment of intangible assets, loss related to plant closure and net (gain) loss on disposal of assets. The Company has reported Adjusted EBITDA because it believes Adjusted EBITDA is a measure commonly reported and widely used by investors as an indicator of a Company's operating performance. The Company believes Adjusted EBITDA assists such investors in comparing a company's performance on a consistent basis. Adjusted EBITDA is not a calculation based on GAAP and should not be considered an alternative to net income in measuring our performance or used as an exclusive measure of cash flow because it does not consider the impact of working capital changes, capital expenditures, debt principal reductions and other sources and uses of cash which are disclosed in our consolidated statements of cash flows. Investors should carefully consider the specific items included in our computation of Adjusted EBITDA. While Adjusted EBITDA has been disclosed herein to permit a more complete comparative analysis of our operating performance relative to other companies, investors should be cautioned that Adjusted EBITDA as reported by us may not be comparable in all instances to Adjusted EBITDA as reported by us or by other companies. Adjusted EBITDA amounts may not be fully available for management's discretionary use, due to certain requirements to conserve funds for capital expenditures, debt service and other commitments, and therefore management relies primarily on our GAAP results. Adjusted EBITDA is not intended to represent net income as defined by GAAP and such information should not be considered as an alternative to net income, cash flow from operations or any other measure of performance prescribed by GAAP in the United States.

      Adjusted Net Income and Diluted Earnings Per Share to Net Income Reconciliation
      The following tables (in thousands, except per share amounts) provide a reconciliation of Adjusted Net Income and Diluted Earnings Per Share, non-GAAP (Generally Accepted Accounting Principles) financial measures, to net income, the most directly comparable financial measure calculated and presented in accordance with GAAP, for the three months ended December 31, 2013, September 30, 2013 and December 31, 2012 and the full year ended December 30, 2013 and 2012:



      Three Months Ended



      December 31, 2013


      September 30, 2013


      December 31, 2012

      Net Income (Loss)

      $

      9,718

      $

      13,962

      $

      (508)

      Reconciling items:







           Income tax provision prior to adjustments


      4,553


      7,377


      2,448

           Loss related to plant closure


      6,597


      —


      —

           Charges related to U.S. Attorney investigation


      —


      —


      3,550

           (Gains) loss on disposal of assets


      (39)


      (161)


      1,117

      Adjusted income before income taxes


      20,829


      21,178


      6,607

           Provision for income taxes after adjustments


      6,645


      7,321


      2,570

      Adjusted net income

      $

      14,184

      $

      13,857

      $

      4,037

      Adjusted diluted earnings per share

      $

      0.66

      $

      0.65

      $

      0.20








      Year Ended





      December 31, 2013


      December 31, 2012



      Net Income

      $

      30,515

      $

      4,063



      Reconciling items:







           Income tax provision prior to adjustments


      15,464


      6,895



           Loss related to plant closure


      6,597


      —



           Charges related to U.S. Attorney investigation


      —


      7,990



           (Gains) loss on disposal of assets


      174


      (2,635)



      Adjusted income before income taxes


      52,750


      16,313



           Provision for income taxes after adjustments


      17,740


      5,936



      Adjusted net income

      $

      35,010

      $

      10,377



      Adjusted diluted earnings per share

      $

      1.66

      $

      0.52



      Adjusted net income and Adjusted diluted earnings per share represent net income and diluted earnings per share without loss related to plant closure, charges related to U.S. Attorney investigation, net (gain) loss on disposal of assets and taxes associated with these items. The Company has reported Adjusted net income and Adjusted diluted earnings per share because it believes these measures are widely used by investors as an indicator of a Company's operating performance. The Company believes Adjusted net income and Adjusted diluted earnings per share assist investors in comparing a company's performance on a consistent basis.  Adjusted net income and Adjusted diluted earnings per share are not calculations based on GAAP and should not be considered alternatives to net income or diluted earnings per share in measuring our performance. Investors should carefully consider the specific items included in our computation of Adjusted net income and Adjusted diluted earnings per share. While Adjusted net income and Adjusted diluted earnings per share has been disclosed herein to permit a more complete comparative analysis of our operating performance across time periods and relative to other companies, investors should be cautioned that these measures as reported by us may not be comparable in all instances to Adjusted net income and Adjusted diluted earnings per share as reported by us or by other companies. Adjusted net income and Adjusted diluted earnings per share are not intended to represent net income or diluted earnings per share as defined by GAAP and such information should not be considered as an alternative to net income, diluted earnings per share or any other measure of performance prescribed by GAAP in the United States.

      Logo - http://photos.prnewswire.com/prnh/20120717/NE41641LOGO

      SOURCE Omega Protein Corporation

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.